JOP20220246A1 - مثبطات rip1k - Google Patents
مثبطات rip1kInfo
- Publication number
- JOP20220246A1 JOP20220246A1 JOP/2022/0246A JOP20220246A JOP20220246A1 JO P20220246 A1 JOP20220246 A1 JO P20220246A1 JO P20220246 A JOP20220246 A JO P20220246A JO P20220246 A1 JOP20220246 A1 JO P20220246A1
- Authority
- JO
- Jordan
- Prior art keywords
- rip1k
- inhibitors
- compounds
- kinase
- rip1
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 3
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
يتعلق الاختراع الحالي بالكشف في هذه الوثيقة عن مركبات كيناز تثبيطية، مثل مركبات مثبط كيناز لبروتين تفاعل-مستقبل 1 (RIP1)، وكذلك تركيبات صيدلية وتوليفات تشتمل على تلك المركبات التثبيطية. يمكن استخدام المركبات، و/أو التركيبات الصيدلية، و/أو التوليفات التي يتم الكشف عنها لعلاج أو الوقاية من مرض أو حالة مرتبطة بالكيناز، تحديدًا مرض أو حالة مرتبطة بـ RIP1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004404P | 2020-04-02 | 2020-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220246A1 true JOP20220246A1 (ar) | 2023-01-30 |
Family
ID=75747027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0246A JOP20220246A1 (ar) | 2020-04-02 | 2022-10-04 | مثبطات rip1k |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11584758B2 (ar) |
| EP (1) | EP4126864A1 (ar) |
| JP (2) | JP2023520046A (ar) |
| KR (1) | KR20220161433A (ar) |
| CN (1) | CN115867548B (ar) |
| AR (1) | AR121717A1 (ar) |
| AU (1) | AU2021246147B2 (ar) |
| BR (1) | BR112022019492A2 (ar) |
| CA (1) | CA3173432A1 (ar) |
| CL (1) | CL2022002695A1 (ar) |
| CO (1) | CO2022014137A2 (ar) |
| CR (1) | CR20220492A (ar) |
| DO (1) | DOP2022000215A (ar) |
| EC (1) | ECSP22076856A (ar) |
| IL (1) | IL296916A (ar) |
| JO (1) | JOP20220246A1 (ar) |
| MX (1) | MX2022012305A (ar) |
| PE (1) | PE20230560A1 (ar) |
| PH (1) | PH12022552638A1 (ar) |
| SA (1) | SA522440778B1 (ar) |
| TW (1) | TW202204364A (ar) |
| UA (1) | UA128751C2 (ar) |
| WO (1) | WO2021203011A1 (ar) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI763630B (zh) * | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| UA128160C2 (uk) | 2018-05-03 | 2024-04-24 | Райджел Фармасутікалс, Інк. | Сполуки, що інгібують rip1, а також способи їх одержання та застосування |
| EA202092580A1 (ru) | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| KR102793185B1 (ko) | 2019-09-06 | 2025-04-09 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| AU2021225921A1 (en) * | 2020-02-28 | 2022-09-22 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease |
| AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| IL314082A (en) | 2022-01-12 | 2024-09-01 | Denali Therapeutics Inc | Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide |
| WO2023138317A1 (zh) * | 2022-01-21 | 2023-07-27 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
| CN116640156B (zh) * | 2022-02-22 | 2025-10-24 | 上海齐鲁制药研究中心有限公司 | Ripk1抑制剂 |
| US20250197390A1 (en) * | 2022-03-16 | 2025-06-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused heterocyclic compound, and preparation method therefor and medical use thereof |
| CN118108633A (zh) * | 2024-01-17 | 2024-05-31 | 浙江工业大学 | 一种l-草铵膦中间体(s)-2-(((苄氧基)羰基)氨基)丁-3-烯酸甲酯的制备方法 |
| WO2025153090A1 (zh) * | 2024-01-19 | 2025-07-24 | 无锡奕拓医药科技有限责任公司 | 一种多并环化合物、其药物组合物及其用途 |
| EP4652998A1 (en) * | 2024-05-21 | 2025-11-26 | Technische Universität München | Treatment of receptor-interacting protein kinase 1- mediated disease with eclitasertib |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090099242A1 (en) | 2007-08-15 | 2009-04-16 | Cuny Gregory D | Heterocyclic inhibitors of necroptosis |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| CN107207485A (zh) | 2015-02-13 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑三唑‑3‑甲酰胺的晶型 |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| US10426758B2 (en) | 2015-10-13 | 2019-10-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| JP6754772B2 (ja) * | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MA44007A (fr) * | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3585782A1 (en) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CA3068305A1 (en) * | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
| WO2019204537A1 (en) * | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| EA202092580A1 (ru) | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| UA128160C2 (uk) | 2018-05-03 | 2024-04-24 | Райджел Фармасутікалс, Інк. | Сполуки, що інгібують rip1, а також способи їх одержання та застосування |
| EP3816163A4 (en) | 2018-06-26 | 2022-04-13 | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences | CELL NECROSIS INHIBITORS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF |
| CN109134448B (zh) * | 2018-10-16 | 2020-11-27 | 中南大学湘雅医院 | 杂环化合物及其盐、制备方法、用途和药物 |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CN114008038B (zh) | 2019-05-31 | 2023-01-24 | 南京明德新药研发有限公司 | 作为rip-1激酶抑制剂的双并环类化合物及其应用 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| KR102793185B1 (ko) | 2019-09-06 | 2025-04-09 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 |
| AU2020378407B2 (en) | 2019-11-07 | 2024-02-01 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 inhibitory compounds |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
-
2021
- 2021-03-31 AR ARP210100820A patent/AR121717A1/es unknown
- 2021-04-01 TW TW110112096A patent/TW202204364A/zh unknown
- 2021-04-02 WO PCT/US2021/025598 patent/WO2021203011A1/en not_active Ceased
- 2021-04-02 PH PH1/2022/552638A patent/PH12022552638A1/en unknown
- 2021-04-02 KR KR1020227037796A patent/KR20220161433A/ko active Pending
- 2021-04-02 BR BR112022019492A patent/BR112022019492A2/pt unknown
- 2021-04-02 US US17/221,493 patent/US11584758B2/en active Active
- 2021-04-02 UA UAA202203662A patent/UA128751C2/uk unknown
- 2021-04-02 PE PE2022002161A patent/PE20230560A1/es unknown
- 2021-04-02 CR CR20220492A patent/CR20220492A/es unknown
- 2021-04-02 JP JP2022559872A patent/JP2023520046A/ja active Pending
- 2021-04-02 EP EP21722607.5A patent/EP4126864A1/en active Pending
- 2021-04-02 AU AU2021246147A patent/AU2021246147B2/en active Active
- 2021-04-02 CN CN202180038481.3A patent/CN115867548B/zh active Active
- 2021-04-02 MX MX2022012305A patent/MX2022012305A/es unknown
- 2021-04-02 IL IL296916A patent/IL296916A/en unknown
- 2021-04-02 CA CA3173432A patent/CA3173432A1/en active Pending
-
2022
- 2022-09-30 CO CONC2022/0014137A patent/CO2022014137A2/es unknown
- 2022-09-30 DO DO2022000215A patent/DOP2022000215A/es unknown
- 2022-09-30 EC ECSENADI202276856A patent/ECSP22076856A/es unknown
- 2022-09-30 CL CL2022002695A patent/CL2022002695A1/es unknown
- 2022-10-02 SA SA522440778A patent/SA522440778B1/ar unknown
- 2022-10-04 JO JOP/2022/0246A patent/JOP20220246A1/ar unknown
-
2023
- 2023-01-13 US US18/154,255 patent/US12043629B2/en active Active
-
2024
- 2024-11-08 JP JP2024196081A patent/JP2025032106A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115867548B (zh) | 2025-03-11 |
| CR20220492A (es) | 2023-02-09 |
| CL2022002695A1 (es) | 2023-08-11 |
| JP2023520046A (ja) | 2023-05-15 |
| BR112022019492A2 (pt) | 2022-11-16 |
| EP4126864A1 (en) | 2023-02-08 |
| US20210317135A1 (en) | 2021-10-14 |
| SA522440778B1 (ar) | 2025-07-08 |
| CN115867548A (zh) | 2023-03-28 |
| US20230227469A1 (en) | 2023-07-20 |
| AU2021246147B2 (en) | 2024-01-18 |
| AR121717A1 (es) | 2022-06-29 |
| MX2022012305A (es) | 2023-03-06 |
| UA128751C2 (uk) | 2024-10-09 |
| PE20230560A1 (es) | 2023-03-31 |
| CO2022014137A2 (es) | 2023-03-07 |
| US12043629B2 (en) | 2024-07-23 |
| TW202204364A (zh) | 2022-02-01 |
| US11584758B2 (en) | 2023-02-21 |
| IL296916A (en) | 2022-12-01 |
| KR20220161433A (ko) | 2022-12-06 |
| PH12022552638A1 (en) | 2023-01-16 |
| WO2021203011A1 (en) | 2021-10-07 |
| JP2025032106A (ja) | 2025-03-11 |
| ECSP22076856A (es) | 2023-02-28 |
| CA3173432A1 (en) | 2021-10-07 |
| AU2021246147A1 (en) | 2022-10-20 |
| DOP2022000215A (es) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220246A1 (ar) | مثبطات rip1k | |
| MX2022002719A (es) | Inhibidores heterociclicos de la quinasa rip1. | |
| PH12020551847A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| PH12022550537A1 (en) | Rip1 inhibitory compounds and methods for making and using the same. | |
| PH12020551848A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| PH12022553615A1 (en) | Rip1k inhibitors. | |
| MX2023010624A (es) | Inhibidores heterociclicos de la cinasa rip1. | |
| AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 |